Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

NASDAQ, Purdue's ADF depends on the drug

http://www.purduepharma.com/news-media/2015/01/hysingla-er-hydrocodone-bitartrate-extended-release-tablets-cii-now-available/

Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now Available
A Once-Daily Opioid Formulated with Abuse-Deterrent Properties
Stamford, Conn. – January 26, 2015 – Purdue Pharma today announced the U.S. commercial launch of Hysingla™ ER (hydrocodone bitartrate) extended-release tablets CII, a once-daily (every 24 hours), single-entity medication formulated using Purdue’s proprietary extended-release solid oral platform, RESISTEC™. Hysingla ER is the first and only hydrocodone product to be recognized by the U.S. Food & Drug Administration (FDA) as having abuse-deterrent properties that are expected to deter misuse and abuse via chewing, snorting and injection. However, abuse of Hysingla ER by the intravenous, intranasal, and oral routes is still possible.1

I think it is very interesting that their brand new hydrocodone formulation, Hysingla, has some proprietary ADF called RESISTEC, but reformulated (supposedly ADF) OxyContin does not have this same technology, no mention of RESISTEC anywhere as relates to OxyContin. Not sure what that means. Maybe the FDA has expressed some interest as well. I also note my previous post re: Collegium's recent HAL study proving the ineffectiveness of OxyContin's ADF for crushing and swallowing. Maybe that is what this cancellation is about. You can see the post here (if it is not deleted by a Mod for third time):

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114925235